President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a “win year” after more than a ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving ...
First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD CTx001 is an investigational AAV-based gene therapy designed to deliver ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
C3G and IC-MPGN can be difficult to diagnose because they are so rare and their symptoms are vague and nonspecific. A kidney biopsy is considered the gold standard and usually needed to confirm the ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing ...
Discover large garden ideas to give your outdoor space more beauty and functionality. Think: pathways, trellises, raised beds ...
Learn what the Nipah virus is, how it spreads, and why it has one of the highest fatality rates among infectious diseases.
A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...
Omeros Corporation (NASDAQ:OMER) Q4 2025 Earnings Call Transcript April 1, 2026 Operator: Good afternoon, and welcome to today’s earnings call for Omeros Corporation. [Operator Instructions] Please be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results